

In the claims:

Please amend the following claims as indicated. Please add new claims 35-41.

- 1-13. Canceled.
14. (Currently Amended) The method of claim 17 wherein the Ab1 binding agent is a monoclonal antibody produced by a hybridoma that has ATCC Designation Number HB-12526.
15. (Previously amended) The method of claim 17 wherein the immune response comprises a humoral and cellular immune response.
16. Canceled.
17. (Currently Amended) A method for inducing an immune response to prostate specific antigen comprising administering an Ab1 binding agent to a patient, wherein the Ab1 binding agent specifically binds to an epitope of circulating prostate specific antigen, the epitope comprising the sequence of SEQ ID NO: 1, the Ab1 binding agent being capable of binding to the antigen to form an immunogenic Ab1 binding agent-antigen complex.
- 18-19. Canceled.
20. (Currently Amended) The method of claim 17 wherein the Ab1 binding agent is conjugated to an immunogenic carrier.
21. (Original) The method of claim 20 wherein the immunogenic carrier is keyhole limpet hemocyanin.
- 22-27. Canceled.
28. (Currently Amended) A method for inducing a host to produce an antibody Ab3 antibodies that specifically binds to prostate specific antigen comprising administering to the host a an Ab1 binding agent that specifically binds to an epitope of circulating prostate specific

antigen, wherein the epitope is specifically bound by a monoclonal antibody produced by a hybridoma that has ATCC Designation Number HB-12526.

29. (Currently Amended) The method of claim 28, wherein the Ab1 binding agent specifically binds to SEQ ID NO: 1.
30. (Currently Amended) The method of claim 28, wherein the Ab1 binding agent is a monoclonal antibody produced by a hybridoma that has ATCC Designation Number HB-12526.
31. (Previously added) The method of claim 28, wherein the host generates an immune response comprising a humoral and cellular immune response.
32. (Currently Amended) The methods of claim 28, wherein the Ab1 binding agent is conjugated to an immunogenic carrier.
33. (Previously added) The method of claim 32, wherein the immunogenic carrier is keyhole limpet hemocyanin.
34. (Previously added) The method of claim 28, wherein the host is a human.
35. (New) The method of claim 17, wherein the Ab1 is selected from the group consisting of one member of an immunologic pair; an antibody; a monoclonal antibody; an antibody fragment thereof; a single chain antibody; a humanized antibody or fragment thereof; and a chimeric antibody or fragment thereof. *new Rej. st.*
36. (New) The method of claim 28, wherein the Ab1 is selected from the group consisting of one member of an immunologic pair; an antibody; a monoclonal antibody; an antibody fragment thereof; a single chain antibody; a humanized antibody or fragment thereof; and a chimeric antibody or fragment thereof.
37. (New) The method according to claim 17 or 28, wherein the Ab1 antibody is a xenogenic antibody.

38. (New) The method according to claim 17 or 28, wherein the Ab1 antibody is formulated with an adjuvant.

39. (New) The method according to claim 17 or 28, wherein the Ab1 antibody is administered at a low dose. — how low?

40. (New) The method of claim 39, wherein the low dose is formulated at a dose of from about 0.1 μg to about 2 mg per kilogram of body weight of the patient.

41. (New) The method of claim 39, wherein the low dose is formulated at a dose of from about 1.0 μg to about 200 μg per kilogram of body weight of the patient.